Jiangsu Honghui Equity Investment Management
Shanghai, Shanghaihighlight-capital.com
Overview
A private investment firm founded in 2014, dedicated to creating long-term value by promoting technology innovations. The firm specializes in the healthcare, biomedicine, medical technology, and consumer-related sectors, leveraging its expertise in chemical, biological, and material sciences to invest in companies that enhance manufacturing efficiency and human wellness. It operates globally with offices in Shanghai, Tokyo, Hong Kong, and Boston.
Portfolio Companies
3
Website
highlight-capital.comInvestments
| Company | Date | Stage | Lead |
|---|---|---|---|
| ABM Therapeutics | Jan 2022 | Series B | Co-investor |
| Inmagene | Jun 2021 | Series C | - |
| Beijing Geneplus Technology | Nov 2020 | Series B Extension | Co-investor |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
